Home > Insider Trading > Filing (0000899243-19-003695)

Filing Details

Accession Number:: 0000899243-19-003695
Form Type:: 5
Zero Holdings:: No
Publication Time:: 2019-02-14 18:19:10
Reporting Period:: 2018-12-31

Accepted Time:: 2019-02-14 18:19:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1731831	Eidos Therapeutics Inc.	EIDX	Pharmaceutical Preparations (2834)	463733671

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1742485	Neil Kumar	C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2550 San Francisco CA 94104	Chief Executive Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-12-03	1,750,000	$15.50	21,364,655	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-12-05	1,103,848	$14.01	22,468,503	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-12-06	38,970	$13.34	22,507,473	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-12-07	36,314	$13.94	22,543,787	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-12-07	4,860	$14.36	22,548,647	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-12-10	37,989	$13.29	22,586,636	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-12-10	2,664	$13.96	22,589,300	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
Represents the weighted average purchase price of the shares purchased ranging from $12.79 to $13.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares purchased ranging from $13.33 to $14.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares purchased ranging from $13.34 to $14.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares purchased ranging from $12.85 to $13.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares purchased ranging from $13.86 to $14.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.